-
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trialMorrow DA, Velazquez EJ, DeVore AD et al. -
Phenomapping for Novel Classification of Heart Failure With Preserved Ejection FractionShah SJ, Katz DH, Selvaraj S et al.
-
The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) StudyIbrahim NE, Januzzi JL Jr.
-
Glucose-lowering Drugs or Strategies, Atherosclerotic Cardiovascular Events, and Heart Failure in People With or at Risk of Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomised Cardiovascular Outcome TrialsOR Ghosh-Swaby, SG Goodman, LA Leite et al.
-
Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic DiscoveryAragam KG, Chaffin M, GRADE Investigators.
-
Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF TrialMN Kosiborod, PJhund, KF Docherty et al.
-
Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes MellitusK Ejiri, T Miyoshi, MUSCAT‐HF Study Investigators.
-
Association of Prior Left Ventricular Ejection Fraction With Clinical Outcomes in Patients With Heart Failure With Midrange Ejection FractionA Brann, S Janvanishstaporn, B Greenberg et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
